PCVX - Vaxcyte, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Carlos,
United States
Type: Equity
PCVX price evolution
PCVX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $397.45 | $545.13 | $531.03 | $380.45 |
| Short term investments | $682.78 | $720.55 | $756.03 | $441.59 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $1095.95 | $1295.43 | $1310.32 | $840.67 |
| Long term investments | $163.78 | $169.67 | $154.6 | $128.69 |
| Property, plant & equipment | $110.62 | $27.76 | $34.43 | $34.86 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $311.96 | $200.62 | $192.5 | $167.49 |
| Total investments | $846.55 | $890.22 | $910.63 | $570.27 |
| Total assets | $1407.92 | $1496.06 | $1502.82 | $1008.16 |
| Current liabilities | ||||
| Accounts payable | $14.59 | $15.7 | $16.27 | $11.62 |
| Deferred revenue | ||||
| Short long term debt | $7.11 | $6.03 | $5.99 | $5.95 |
| Total current liabilities | $145.34 | $85.56 | $60.22 | $52.75 |
| Long term debt | $22.11 | $7.78 | $9.22 | $10.64 |
| Total noncurrent liabilities | $22.11 | $7.78 | $9.23 | $10.64 |
| Total debt | $29.22 | $13.81 | $15.21 | $16.59 |
| Total liabilities | $167.45 | $93.34 | $69.44 | $63.39 |
| Shareholders' equity | ||||
| Retained earnings | -$924.39 | -$743.59 | -$650.93 | -$582.59 |
| Other shareholder equity | $0.18 | -$2.29 | -$2.52 | $0.05 |
| Total shareholder equity | $1240.47 | $1402.72 | $1433.38 | $944.77 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $397.45 | $834.66 | $68.98 | $386.2 |
| Short term investments | $682.78 | $96.72 | $176.99 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $1095.95 | $942.55 | $256.35 | $389 |
| Long term investments | $163.78 | $27.42 | $27.99 | |
| Property, plant & equipment | $110.62 | $31.65 | $35.91 | $3.27 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $311.96 | $63.62 | $67.99 | $3.82 |
| Total investments | $846.55 | $124.14 | $204.97 | |
| Total assets | $1407.92 | $1006.18 | $324.34 | $392.83 |
| Current liabilities | ||||
| Accounts payable | $14.59 | $9.79 | $6.76 | $29.79 |
| Deferred revenue | ||||
| Short long term debt | $7.11 | $5.91 | $5.28 | |
| Total current liabilities | $145.34 | $40.52 | $28.72 | $46.86 |
| Long term debt | $22.11 | $12.03 | $11.51 | |
| Total noncurrent liabilities | $22.11 | $12.04 | $11.6 | $0.12 |
| Total debt | $29.22 | $17.94 | $16.78 | |
| Total liabilities | $167.45 | $52.56 | $40.32 | $46.98 |
| Shareholders' equity | ||||
| Retained earnings | -$924.39 | -$522.13 | -$298.64 | -$198.56 |
| Other shareholder equity | $0.18 | -$0.36 | -$0.24 | |
| Total shareholder equity | $1240.47 | $953.61 | $284.02 | $345.84 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $104.15 | $97.42 | $72.69 | $58.08 |
| Selling, general & administrative | $17.53 | $15.61 | $14.46 | $13.11 |
| Total operating expenses | $196.68 | $113.03 | $87.15 | $71.19 |
| Operating income | -$196.68 | -$113.03 | -$87.15 | -$71.19 |
| Income from continuing operations | ||||
| EBIT | -$180.8 | -$92.66 | -$68.34 | -$60.46 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$180.8 | -$92.66 | -$68.34 | -$60.46 |
| Income (for common shares) | -$180.8 | -$92.66 | -$68.34 | -$60.46 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $332.34 | $169.45 | $78.41 | $73.56 |
| Selling, general & administrative | $60.7 | $39.81 | $25.26 | $16.02 |
| Total operating expenses | $468.04 | $232.26 | $103.67 | $89.58 |
| Operating income | -$468.04 | -$232.26 | -$103.67 | -$89.58 |
| Income from continuing operations | ||||
| EBIT | -$402.27 | -$223.48 | -$100.07 | -$89.21 |
| Income tax expense | ||||
| Interest expense | $0 | $0.01 | $0.01 | |
| Net income | ||||
| Net income | -$402.27 | -$223.49 | -$100.08 | -$89.22 |
| Income (for common shares) | -$402.27 | -$223.49 | -$100.08 | -$89.22 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$180.8 | -$92.66 | -$68.34 | -$60.46 |
| Operating activities | ||||
| Depreciation | $2.95 | $2.48 | $2.4 | $2.34 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $13.35 | $13.22 | $12.54 | $9.65 |
| Total cash flows from operations | -$128.81 | -$57.55 | -$62.74 | -$47.69 |
| Investing activities | ||||
| Capital expenditures | -$57.07 | -$7.34 | $2.14 | -$5.61 |
| Investments | $43.14 | $29.62 | -$335.7 | -$442.49 |
| Total cash flows from investing | -$13.93 | $22.28 | -$333.56 | -$448.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.73 | $48.55 | $546.97 | $41.56 |
| Net borrowings | ||||
| Total cash flows from financing | $2.73 | $48.55 | $546.97 | $41.56 |
| Effect of exchange rate | -$7.68 | $1.05 | -$0.08 | $0.02 |
| Change in cash and equivalents | -$147.68 | $14.33 | $150.58 | -$454.21 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$402.27 | -$223.49 | -$100.08 | -$89.22 |
| Operating activities | ||||
| Depreciation | $10.17 | $9.2 | $3.46 | $1.41 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $48.76 | $23.65 | $10.73 | $5.43 |
| Total cash flows from operations | -$296.79 | -$170.6 | -$121.39 | -$46.63 |
| Investing activities | ||||
| Capital expenditures | -$67.88 | -$5.84 | -$6.53 | -$1.1 |
| Investments | -$705.43 | $80.43 | -$205.78 | |
| Total cash flows from investing | -$773.31 | $74.58 | -$212.31 | -$1.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $639.81 | $862.41 | $17.8 | $268.42 |
| Net borrowings | -$0.06 | |||
| Total cash flows from financing | $639.81 | $861.55 | $17.8 | $374.87 |
| Effect of exchange rate | -$6.69 | $0.14 | -$0.44 | $0.09 |
| Change in cash and equivalents | -$436.97 | $765.67 | -$316.34 | $327.22 |
News
Fundamentals
| Market cap | $5.81B |
|---|---|
| Enterprise value | $5.44B |
| Shares outstanding | 95.36M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$392.10M |
| EBIT | -$402.27M |
| Net Income | -$402.27M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -14.43 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -13.87 |
| EV/EBIT | -13.52 |
| P/S ratio | N/A |
| P/B ratio | 4.68 |
| Book/Share | 13.01 |
| Cash/Share | 4.17 |
| EPS | -$4.22 |
|---|---|
| ROA | -29.72% |
| ROE | -32.04% |
| Debt/Equity | 0.13 |
|---|---|
| Net debt/EBITDA | 0.59 |
| Current ratio | 7.54 |
| Quick ratio | 7.54 |